UCA1-AS1 and colorectal carcinoma: In vitro experiments showed that treatment with the glutamine inhibitor CB839 reversed or partially reversed the promotion of LINC01764 overexpression on the proliferation, migration and 5‐FU resistance of CRC cells (Figure S6A–C).